Saxenda vs. Farxiga

See how Saxenda and Farxiga compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Saxenda is a daily injectable GLP-1 approved for chronic weight management, while Farxiga is a once-daily pill approved for type 2 diabetes, heart failure, and chronic kidney disease.

  • Saxenda's most common side effects are gastrointestinal, such as nausea and diarrhea, while Farxiga's most common side effects are genital and urinary infections.

  • These drugs treat different core conditions and are rarely substitutes, though some patients with type 2 diabetes and obesity may end up using both.

Saxenda vs. Farxiga Drug Summary

Saxenda

Saxenda (liraglutide) is a GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in adolescents 12 to 17 with obesity. It is injected once daily under the skin and works by reducing appetite and slowing stomach emptying. It is not approved to treat diabetes.

Farxiga

Farxiga (dapagliflozin) is an SGLT2 inhibitor taken as a once-daily oral tablet. It is approved for blood sugar control in type 2 diabetes, reducing heart failure hospitalization, treating heart failure, and slowing chronic kidney disease progression. It works by causing the kidneys to remove excess glucose through urine.

Saxenda vs. Farxiga Side Effects

Saxenda

Most common
Nausea (up to 39.3%)
Diarrhea (up to 20.9%)
Constipation (up to 19.4%)
Vomiting (up to 15.7%)

Farxiga

Most common
Female genital mycotic infections (up to 6.9%)
Nasopharyngitis (up to 6.3%)
Urinary tract infections (up to 4.3%)
Back pain (up to 4.2%)

Saxenda vs. Farxiga Dosage

Saxenda

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 3 mg once daily Week 5 onward
Dose changes 4 increases Every week

Farxiga

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 10 mg once daily If needed
Dose changes 1 increase As tolerated

Saxenda vs. Farxiga Indications

Saxenda

Saxenda is FDA-approved for chronic weight management in adults with obesity or overweight who also have a weight-related condition like high blood pressure or type 2 diabetes. It's also approved for adolescents aged 12 to 17 with obesity. It is not approved to treat diabetes itself, even though many people who take it also have type 2 diabetes.

  • Chronic weight management in adults with obesity

  • Weight management with a related condition like high blood pressure

  • Adolescents 12-17 with obesity

  • Not approved for treating diabetes directly

Farxiga

Farxiga is FDA-approved for blood sugar control in adults and children 10 and older with type 2 diabetes. It also carries approvals for reducing heart failure hospitalization, treating heart failure across ejection fraction types, and slowing chronic kidney disease progression. It is not approved for type 1 diabetes or diabetic ketoacidosis.

  • Blood sugar control in type 2 diabetes (age 10+)

  • Reduce risk of heart failure hospitalization

  • Treatment of heart failure, any ejection fraction

  • Slow chronic kidney disease progression

Saxenda vs. Farxiga Pros and Cons

Saxenda

Saxenda has a long track record for weight loss as one of the earliest GLP-1 drugs approved specifically for obesity, though it requires a daily injection rather than a weekly one. Insurance coverage for weight-loss indications is often limited, and many plans require prior authorization or exclude it outright.

Pros

  • FDA-approved specifically for chronic weight loss

  • Also approved for adolescents 12-17

  • Long track record since its 2014 approval

Cons

  • Requires a daily injection, not weekly

  • Not approved for diabetes management

  • Boxed warning for thyroid C-cell tumor risk

Farxiga

Farxiga covers a broad range of conditions beyond diabetes, including heart failure and chronic kidney disease, making it useful for patients with overlapping cardiovascular and renal risk. It's taken as a once-daily pill, which many people find easier than an injection, but it is not approved for weight loss.

Pros

  • Once-daily oral tablet, no injections

  • Also approved for heart failure and kidney disease

  • Approved use across four separate conditions

Cons

  • Not approved for weight management

  • Risk of genital and urinary tract infections

  • Rare risk of Fournier's gangrene and ketoacidosis

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.